IIP

argenx Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, October 27, 2022
Company, FC, LinkedIn, GMG, Investor, BLA, SIMPLE, Webcast, Research, Income, Neonatal Fc receptor, Public expenditure, Degenerative disease, Instagram, IIP, Leo Pharma, Janssen, Twitter, Therapy, Marketing, Income tax, SC, Sale, Online gambling, Pharmaceutical industry, Video game, EU

Collaboration revenue for the third quarter and year-to-date in 2022 was $6.7 million and $9.3 million, respectively, compared to $0.1 million and $471.3 million for the same periods in 2021.

Key Points: 
  • Collaboration revenue for the third quarter and year-to-date in 2022 was $6.7 million and $9.3 million, respectively, compared to $0.1 million and $471.3 million for the same periods in 2021.
  • Other operating income for the third quarter and year-to-date in 2022 was $8.5 million, and $26.6 million, respectively, compared to $6.2 million and $34.5 million for the same periods in 2021.
  • During the nine months ended September 30, 2022, and September 30, 2021, the fair value of the argenx profit share in AgomAb Therapeutics NV increased by $4.3 million and $11.2 million respectively.
  • The third quarter 2022 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 pm CEST/8:30 am ET.

argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022

Retrieved on: 
Thursday, October 20, 2022
Degenerative disease, LinkedIn, Neonatal Fc receptor, Company, Euronext, CET, Webcast, Twitter, Instagram, Investor, FC, IIP, Pharmaceutical industry, EU

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors .

Key Points: 
  • A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors .
  • A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.
  • argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan.

Innovative Industrial Properties Declares Third Quarter 2022 Dividends

Retrieved on: 
Thursday, September 15, 2022
Cannabis, Search Engine Optimization, Search Engine Marketing, Specialty, Natural Resources, Commercial Building & Real Estate, Construction & Property, Retail, Public Relations, Investor Relations, Communications, Alternative Medicine, REIT, Health, Ownership, New, Private Securities Litigation Reform Act, Acquisition, Terminology, IIP, NYSE, Trust, Holding company

The common stock dividends declared for the twelve months ending September 30, 2022, of $6.80 per common share represent an increase of $1.34, or 25%, over dividends declared for the twelve months ended September 30, 2021.

Key Points: 
  • The common stock dividends declared for the twelve months ending September 30, 2022, of $6.80 per common share represent an increase of $1.34, or 25%, over dividends declared for the twelve months ended September 30, 2021.
  • The dividends are payable on October 14, 2022 to stockholders of record at the close of business on September 30, 2022.
  • Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated cannabis facilities.
  • Innovative Industrial Properties, Inc. has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017.

argenx Appoints Camilla Sylvest to Board of Directors

Retrieved on: 
Thursday, September 8, 2022
Euronext, Neonatal Fc receptor, Twitter, IIP, Board, FC, Instagram, Degenerative disease, Board of directors, Company, LinkedIn, Management, EU

Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors.

Key Points: 
  • Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors.
  • Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability.
  • The voting result and all documents relating to the shareholders meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings .
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.

Innovative Industrial Properties Acquires Massachusetts Property and Expands Long-Term Real Estate Partnership with Curaleaf

Retrieved on: 
Thursday, September 1, 2022
Commercial Building & Real Estate, Construction & Property, REIT, Cannabis, Specialty, Alternative Medicine, Health, Retail, Natural Resources, People, Statistics, CSE, Trust, NYSE, EBITDA, IIP, Ownership, REIT, New, River, Terminology, Private Securities Litigation Reform Act, Acquisition, Real estate, Drug, Curaleaf

Curaleaf is a vertically-integrated operator in Massachusetts, with four dispensaries and two cultivation and processing facilities (including this facility).

Key Points: 
  • Curaleaf is a vertically-integrated operator in Massachusetts, with four dispensaries and two cultivation and processing facilities (including this facility).
  • Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated cannabis facilities.
  • Innovative Industrial Properties, Inc. has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017.
  • All statements other than historical facts, including, without limitation, statements regarding the Massachusetts property and Curaleaf, are forward-looking statements.

argenx to Present at Wells Fargo Healthcare Conference

Retrieved on: 
Wednesday, August 31, 2022
Euronext, Degenerative disease, Neonatal Fc receptor, IIP, LinkedIn, FC, Instagram, Conference, Company, Twitter, Investor, Webcast, Pharmaceutical industry, EU

Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:00 a.m. E.T.

Key Points: 
  • Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:00 a.m. E.T.
  • A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors.
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.
  • argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan.

argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022

Retrieved on: 
Thursday, July 28, 2022
FC, Instagram, Twitter, Person, XZ, Company, LinkedIn, Degenerative disease, Proxy, Euronext, IIP, Neonatal Fc receptor, Pharmaceutical industry

The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders.

Key Points: 
  • The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders.
  • The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices.
  • argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.
  • The Company will provide a live audio-webcast of the general meeting to enable as many shareholders as possible to attend.

argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update

Retrieved on: 
Thursday, July 28, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Sale, FC, Medication, Income tax, Research, Instagram, Food, Twitter, Medicines and Healthcare products Regulatory Agency, PMDA, Marketing, Income, Therapy, SIMPLE, Webcast, Janssen, FDA, Company, LinkedIn, Pharmaceuticals and Medical Devices Agency, Degenerative disease, Public expenditure, Investor, IIP, Neonatal Fc receptor, Video game, Pharmaceutical industry, Cryptocurrency

Collaboration revenue for the second quarter and year-to-date in 2022 was $0.4 million and $2.6 million, respectively, compared to $312.2 million and $470.4 million for the same periods in 2021.

Key Points: 
  • Collaboration revenue for the second quarter and year-to-date in 2022 was $0.4 million and $2.6 million, respectively, compared to $312.2 million and $470.4 million for the same periods in 2021.
  • Other operating income for the second quarter and year-to-date in 2022 was $10.0 million, and $18.1 million, respectively, compared to $7.8 million and $28.2 million for the same periods in 2021.
  • During the three months ended June 30, 2022, the fair value of the argenx profit share in AgomAb Therapeutics NV increased by $4.3 million.
  • The half-year financial results and second quarter 2022 business update will be discussed during a conference call and webcast presentation today at 2:30 pm CEST/8:30 am ET.

argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022

Retrieved on: 
Thursday, July 21, 2022
Instagram, Degenerative disease, CET, FC, Webcast, Euronext, Company, Investor, Twitter, IIP, LinkedIn, Neonatal Fc receptor, Pharmaceutical industry

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors .

Key Points: 
  • A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors .
  • A replay of the webcast will be available on the argenx website for approximately one year following the call.
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.
  • argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan.

Innovative Industrial Properties Expands Real Estate Partnership with Green Thumb Industries at Pennsylvania Property

Retrieved on: 
Thursday, June 30, 2022
Cannabis, Retail, Commercial Building & Real Estate, Natural Resources, Specialty, Construction & Property, REIT, Acquisition, Patient, Caregiver, REIT, RISE, Pennsylvania Department of Health, Health, The Dogwalker, Exercise, Ownership, CSE, Green Thumb, Trust, Terminology, Workplace, Pennsylvania General Assembly, United, New, IIP, Statistics, Pennsylvania Department of Transportation, Partnership, HVAC, Private Securities Litigation Reform Act, NYSE, Cannabis, Justice Select Committee, Helene Curtis Industries, Inc., Time, Thumb, Program, Marijuana Business Daily, Property management, Drug, Self storage, Heating, ventilation, and air conditioning, Green

We are grateful for the continued partnership with IIP at our Danville facility, said Green Thumb Founder and Chief Executive Officer Ben Kovler.

Key Points: 
  • We are grateful for the continued partnership with IIP at our Danville facility, said Green Thumb Founder and Chief Executive Officer Ben Kovler.
  • Details of the IIP Pennsylvania property are as follows:
    IIP originally acquired the property for $20.3 million and entered into a long-term lease with Green Thumb in 2019 and under the lease made available $19.3 million for qualifying improvements to the property.
  • We are proud to have supported Green Thumb as their long-term real estate partner since 2019, said Paul Smithers, IIPs President and Chief Executive Officer.
  • Innovative Industrial Properties, Inc. has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017.